Moreover, in myeloma, an enhancement in the expression of receptor activator of nuclear factor kappa B ligand (RANKL) may lead to NF-κB and AP-1-mediated increased bone resorption [60,61]. This evidence concerns the gene NFKB1 and plasma cell myeloma.